Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cell body

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,412 result(s) found for: Cell body. Displaying page 69 of 71.
    «« First « Previous 63  64  65  66  67  68  69  70  71  Next»
    EudraCT Number: 2021-005911-30 Sponsor Protocol Number: ARGX-113-2106 Start Date*: 2022-12-27
    Sponsor Name:argenx BV
    Full Title: A Phase 2, Randomized, Placebo-controlled, Parallel Group, Double-blind, Proof-of-concept Study to Evaluate the Safety and Efficacy of Intravenous Efgartigimod in Adult Participants With Primary Sj...
    Medical condition: Primary Sjögren’s Syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10042846 Syndrome Sjogren's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2010-018563-41 Sponsor Protocol Number: SL0009 Start Date*: 2011-05-25
    Sponsor Name:UCB Inc.
    Full Title: A phase 3, randomized, double-blind, placebo-controlled, multicenter study of the efficacy and safety of four 12-week treatment cycles (48 weeks total) of Epratuzumab in systemic lupus erythematosu...
    Medical condition: Systemic Lupus Erythmatosus
    Disease: Version SOC Term Classification Code Term Level
    17.0 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Completed) DE (Completed) CZ (Completed) GB (Completed) BG (Completed) LT (Completed) EE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-012816-41 Sponsor Protocol Number: D1680L00002 Start Date*: 2009-08-12
    Sponsor Name:AstraZeneca AB
    Full Title: A 52-Week, Randomised, Double-Blind, Active-Controlled, Multi-Centre Phase IIIb/IV Study to Evaluate the Efficacy and Tolerability of Saxagliptin Compared to Glimepiride in Elderly Patients with Ty...
    Medical condition: Non-insulin dependent type 2 diabetes mellitus in elderly patients (≥ 65 years)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10029505 Non-insulin-dependent diabetes mellitus LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) DK (Completed) FI (Completed) ES (Completed) NO (Completed) AT (Completed) FR (Completed) GR (Completed) IT (Completed) GB (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2012-003354-89 Sponsor Protocol Number: 5172-035 Start Date*: 2013-03-28
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. USA
    Full Title: A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of the combination regimen of MK-5172 and MK-8742 +/-Ribavirin (RBV) in Subjects with Chronic Hepatitis C Virus Infection
    Medical condition: Hepatitis C Virus Genotype 1 (HCV GT 1)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) DK (Completed) HU (Completed) ES (Completed) SE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-004015-20 Sponsor Protocol Number: CDRB436G2201 Start Date*: 2018-01-09
    Sponsor Name:Novartis Pharma AG
    Full Title: Phase II open-label global study to evaluate the effect of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive Low Grade Glioma (LGG) or...
    Medical condition: Paediatric patients with BRAF V600 mutation positive Low Grade Glioma (LGG) or relapsed or refractory High Grade Glioma (HGG)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065443 Malignant glioma PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SE (Completed) CZ (Completed) DE (Completed) ES (Ongoing) IT (Completed) FI (Completed) DK (Completed) FR (Completed) NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003447-11 Sponsor Protocol Number: C-145-04 Start Date*: 2017-10-27
    Sponsor Name:Iovance Biotherapeutics, Inc.
    Full Title: A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma
    Medical condition: Recurrent, metastatic, or persistent Cervical Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10008229 Cervical cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Prematurely Ended) ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000780-40 Sponsor Protocol Number: D5740C00002 Start Date*: 2014-11-11
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of the Safety and Efficacy of Roxadustat in the Treatment of Anemia in Dialysis Patients
    Medical condition: Anemia in chronic kidney disease patients with dialysis
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004857 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) SK (Completed) HU (Completed) ES (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-003842-34 Sponsor Protocol Number: MK-5592-127 Start Date*: Information not available in EudraCT
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 2, Open-Label, Single-Arm, Sequential-Panel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Posaconazole (POS, MK-5592) Intravenous and Powder for Oral Suspension Formul...
    Medical condition: Invasive Fungal Infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10017533 Fungal infection PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) Outside EU/EEA BE (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-003595-12 Sponsor Protocol Number: ADVL1322-VEG116731 Start Date*: 2013-09-04
    Sponsor Name:GlaxoSmithKline
    Full Title: A Phase II Study of Pazopanib in Children, Adolescents and Young Adults with Refractory Solid Tumors.
    Medical condition: relapsed solid tumours in children, adolescents and young adults.
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA CZ (Completed) SK (Completed) ES (Completed) HU (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-018565-26 Sponsor Protocol Number: SL0010 Start Date*: 2011-01-16
    Sponsor Name:UCB Inc.
    Full Title: A phase 3, randomized, double-blind, placebo-controlled, multicenter study of the efficacy and safety of four 12-week treatment cycles (48 weeks total) of Epratuzumab in systemic lupus erythematosu...
    Medical condition: Systemic Lupus Erythmatosus
    Disease: Version SOC Term Classification Code Term Level
    17.0 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) DE (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005543-22 Sponsor Protocol Number: TKT028 Start Date*: 2008-06-19
    Sponsor Name:Shire Human Genetic Therapies, Inc. (Shire HGT)
    Full Title: A Multi-center, Open-Label, Randomized Study Evaluating the Safety and Efficacy of Three Dosing Regimens of Replagal Enzyme Replacement Therapy in Adult Patients with Fabry Disease
    Medical condition: Fabry Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10016016 Fabry's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) FI (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2013-002773-21 Sponsor Protocol Number: EMR700461-023 Start Date*: 2014-02-20
    Sponsor Name:Merck KGaA
    Full Title: A Phase IIb, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept in Subjects With Systemic Lupus Erythematosus (SLE)
    Medical condition: Systemic Lupus Erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) BG (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003775-20 Sponsor Protocol Number: HGT-MLD-071 Start Date*: 2013-09-11
    Sponsor Name:Shire Human Genetics Therapies Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
    Full Title: An Open-label Extension of Study HGT-MLD-070 Evaluating Long Term Safety and Efficacy of Intrathecal Administration of HGT-1110 in Patients with Metachromatic Leukodystrophy
    Medical condition: Treatment of Metachromatic Leukodystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10067609 Metachromatic leukodystrophy PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) CZ (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002499-15 Sponsor Protocol Number: A536-04 Start Date*: 2012-12-19
    Sponsor Name:ACCELERON PHARMA INC
    Full Title: A Phase 2, Open-Label, Ascending Dose Study to Evaluate the Effects of ACE-536 in Patients with β-Thalassemia Intermedia
    Medical condition: β-thalassemia intermedia
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004850 10062923 Thalassemia intermedia LLT
    15.1 100000004850 10054660 Thalassemia beta LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2013-003320-36 Sponsor Protocol Number: 190342-038 Start Date*: 2015-03-02
    Sponsor Name:Allergan Limited
    Full Title: Safety and Efficacy of Brimonidine Posterior Segment Drug Delivery System in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration (BEACON Study)
    Medical condition: Geographic Atrophy Secondary to Age-related Macular Degeneration
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10025409 Macular degeneration PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023310-31 Sponsor Protocol Number: MagicBullet/COLMER Start Date*: 2011-02-07
    Sponsor Name:Consorcio de apoyo a la Investigación Biomédica en Red (CAIBER)
    Full Title: Ensayo clínico en fase IV aleatorizado, abierto, multicéntrico y de no inferioridad para comparar la seguridad y la eficacia de colistina iv. con meropenem iv. en el tratamiento de la neumonía asoc...
    Medical condition: Neumonía asociada a ventilación mecánica
    Disease: Version SOC Term Classification Code Term Level
    13 10052596 Neumonia nosocomial LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-002413-11 Sponsor Protocol Number: PRI01C Start Date*: 2012-02-07
    Sponsor Name:Sanofi Pasteur MSD S.N.C
    Full Title: A phase III open-label randomised study, to evaluate the immunogenicity and safety of the concomitant administration of V419 (PR5I) given at 2, 3 and 4 months of age with two types of meningococcal...
    Medical condition: PR5I is developed to provide active immunization against diphtheria, tetanus, pertussis, poliomyelitis (caused by poliovirus Types 1, 2 and 3), invasive disease caused by Haemophilus influenza ty...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10054183 Tetanus immunization LLT
    14.1 10022891 - Investigations 10019743 Hepatitis B virus (HBV) LLT
    14.1 10042613 - Surgical and medical procedures 10054181 Hepatitis B immunization LLT
    14.1 10042613 - Surgical and medical procedures 10069593 Pertussis immunization LLT
    14.1 10042613 - Surgical and medical procedures 10054180 Diphtheria immunization LLT
    14.1 10042613 - Surgical and medical procedures 10053386 Poliomyelitis vaccine LLT
    14.1 10042613 - Surgical and medical procedures 10069543 Hemophilus influenzae type b immunization LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-004847-35 Sponsor Protocol Number: PredEver_first Start Date*: 2012-09-07
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: Treatment of newly diagnosed moderate or severe chronic graft-versus-host disease with prednisone and everolimus (PredEver first) - A prospective multicenterphase IIA study -
    Medical condition: chronic Graft versus Host Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021428 - Immune system disorders 10018799 GVHD LLT
    14.1 10021428 - Immune system disorders 10063109 Transfusion associated GVHD LLT
    14.1 10021428 - Immune system disorders 10068907 CGVHD LLT
    14.1 10021428 - Immune system disorders 10018653 Graft-versus-host disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004322-15 Sponsor Protocol Number: V503-IC Start Date*: 2018-02-09
    Sponsor Name:UZ Leuven
    Full Title: An Open-label phase III study to investigate the safety, tolerability and immunogenicity of a nine-valent human papillomavirus (HPV) vaccine (Gardasil®9) in solid organ transplant recipients and HI...
    Medical condition: Immune response to HPV vaccination in HIV-patients and Solid Organ Transplant patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10074286 Immunocompromised LLT
    20.0 100000004848 10020180 HIV positive LLT
    20.0 100000004865 10023438 Kidney transplant LLT
    20.0 100000004865 10007611 Cardiac transplant LLT
    20.0 100000004865 10019248 Heart & lung transplant LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2008-005128-10 Sponsor Protocol Number: H9X-MC-GBCK Start Date*: 2009-03-09
    Sponsor Name:Eli Lilly and Company - Indianapolis
    Full Title: Assessment of Dose-Dependent Effects of LY2189265 on Glycemic Control in Patients with Type 2 Diabetes Treated only with Lifestyle Interventions
    Medical condition: Type II Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012601 Diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 63  64  65  66  67  68  69  70  71  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 12 14:54:53 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA